CAPLYTA Hits Primary Endpoint in Pivotal Bipolar Mania Trial, Rapid Symptom Reduction at Week 3
JNJ sits 56% above its 52-week low of $173.33 on elevated volume (2.2× avg).
Summary
J&J's CAPLYTA (lumateperone) met its primary endpoint in a pivotal Phase 3 study for bipolar mania, showing statistically significant and rapid reduction in manic symptoms by Week 3, with a 4.8-point greater YMRS reduction vs placebo and benefits from Day 3; response rate was 45.8% vs 20.9%. The drug was well-tolerated, with dry mouth and nausea as the most common adverse events. A second pivotal study (Study 452) is completed with data analysis underway. This is the first report of these results and represents a meaningful expansion opportunity for CAPLYTA, which is already approved for schizophrenia and bipolar depression. Positive pivotal data in bipolar mania could support a supplemental regulatory filing and broaden the drug's market. The news follows a period of strong pipeline momentum for J&J, including the OTTAVA robotic system authorization and Tecvayli/Talvey combination data. Investors will watch for detailed efficacy data and regulatory next steps.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Caplyta showed a 4.8-point greater YMRS reduction vs placebo at Week 3, with benefits from Day 3; response rate 45.8% vs 20.9%. A second pivotal study (Study 452) is completed with data analysis underway.
At the time of this announcement, JNJ was trading at $270.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $650.6B. The 52-week trading range was $173.33 to $281.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.